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BACKGROUND: Heavy menstrual bleeding affects the physical endometrial ablation group (difference, 50.5 points; 95% confidence in-
functioning and social well-being of many women. The levonorgestrel-
releasing intrauterine system and endometrial ablation are 2 frequently
applied treatments in women with heavy menstrual bleeding.
OBJECTIVE: This study aimed to compare the effectiveness of the
levonorgestrel-releasing intrauterine system with endometrial ablation in
women with heavy menstrual bleeding.
STUDY DESIGN: This multicenter, randomized controlled, non-
inferiority trial was performed in 26 hospitals and in a network of general
practices in the Netherlands. Women with heavy menstrual bleeding, aged
34 years and older, without a pregnancy wish or intracavitary pathology
were randomly allocated to treatment with either the levonorgestrel-
releasing intrauterine system (Mirena) or endometrial ablation, per-
formed with a bipolar radiofrequency device (NovaSure). The primary
outcome was blood loss at 24 months, measured with a Pictorial Blood
Loss Assessment Chart score. Secondary outcomes included reinter-
vention rates, patient satisfaction, quality of life, and sexual function.
RESULTS:We registered 645 women as eligible, of whom 270 women
provided informed consent. Of these, 132 women were allocated to the
levonorgestrel-releasing intrauterine system (baseline Pictorial Blood Loss
Assessment Chart score, 616) and 138 women to endometrial ablation
(baseline Pictorial Blood Loss Assessment Chart score, 630). At 24
months, mean Pictorial Blood Loss Assessment Chart scores were 64.8 in
the levonorgestrel-releasing intrauterine system group and 14.2 in theCite this article as: Beelen P, van den Brink MJ, Herman
MC, et al. Levonorgestrel-releasing intrauterine system
versus endometrial ablation for heavy menstrual
bleeding. Am J Obstet Gynecol 2021;224:187.e1-10.
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https://doi.org/10.1016/j.ajog.2020.08.016terval, 4.3e96.7; noninferiority, P¼.87 [25 Pictorial Blood Loss
Assessment Chart point margin]). Compared with 14 women (10%) in the
endometrial ablation group, 34 women (27%) underwent a surgical
reintervention in the levonorgestrel-releasing intrauterine system group
(relative risk, 2.64; 95% confidence interval, 1.49e4.68). There was no
significant difference in patient satisfaction and quality of life between the
groups.
CONCLUSION: Both the levonorgestrel-releasing intrauterine system
and endometrial ablation strategies lead to a large decrease in menstrual
blood loss in women with heavy menstrual bleeding, with comparable
quality of life scores after treatment. Nevertheless, there was a significant
difference in menstrual blood loss in favor of endometrial ablation, and we
could not demonstrate noninferiority of starting with the levonorgestrel-
releasing intrauterine system. Women who start with the levonorgestrel-
releasing intrauterine system, a reversible and less invasive treatment,
are at an increased risk of needing additional treatment compared
with women who start with endometrial ablation. The results of this study
will enable physicians to provide women with heavy menstrual bleeding
with the evidence to make a well-informed decision between the 2
treatments.
Key words: excessive uterine bleeding, intrauterine device, menor-
rhagia, Mirena, NovaSureIntroduction
Around 30% of women worldwide
experience heavy menstrual bleeding
(HMB). It poses a major burden because
it negatively influences physical activity,
work productivity, and sexual life and isa common reason for consulting a gy-
necologist.1,2 In view of its high preva-
lence and major impact on the quality of
life (QoL), effective treatment is of
utmost importance.
The National Institute for Health and
Care Excellence guideline on HMB rec-
ommends the levonorgestrel-releasing
intrauterine system (LNG-IUS; Mirena,
Bayer HealthCare Pharmaceuticals,
Berlin, Germany) 52mg as the treatment
of first choice.2 Randomized controlled
trials (RCTs) comparing the LNG-IUS
with oral medication have shown
significantly reduced menstrual bleeding
and increased QoL in favor of the LNG-
IUS.3,4 Nevertheless, approximately 40%
of women discontinue the LNG-IUSFEBRUARY 2021 Ameriwithin 2 years because of a lack of
effectiveness, irregular or prolonged
bleeding, abdominal pain, or progesto-
genic side effects.3,5
Alternative surgical options for treat-
ing HMB in women without future
pregnancy wish are endometrial ablation
(EA) and hysterectomy. Hysterectomy is
a definitive solution, but it is an invasive
option, with a risk of serious complica-
tions.6 The EA procedure is a minimally
invasive alternative to hysterectomy that
aims to destroy or remove the endome-
trial tissue. Bipolar radiofrequency EA
results in amenorrhea in 50% of women,
satisfaction rates between 80% and 96%,
and reported reintervention rates
around 10%.7e10can Journal of Obstetrics & Gynecology 187.e1
AJOG at a Glance
Why was this study conducted?
The levonorgestrel-releasing intrauterine system (LNG-IUS) and endometrial
ablation (EA) are 2 frequently used treatments in women with heavy menstrual
bleeding (HMB). Counseling women with HMB is challenging because it is un-
clear which of these 2 treatments is more effective.
Key findings
Both treatment strategies lead to a large decrease in menstrual blood loss, but the
EA strategy results in the least amount of menstrual blood loss. Patient satis-
faction, quality of life, and sexual functioning are comparable between both
strategies. Women treated with the LNG-IUS are at an increased risk of receiving
another intervention to achieve the desired result.
What does this add to what is known?
These results on multiple outcomes enable physicians to provide women with
complete information so that they can make a well-informed decision about
treatment.
Original Research GYNECOLOGY ajog.orgThe LNG-IUS seems superior to oral
medication, but the evidence on the
effectiveness of the LNG-IUS compared
with EA is inconclusive. Previous studies
show conflicting results on bleeding
scores, satisfaction, and
reinterventions.6,11e19 Moreover, these
studies suffered from a risk of attrition
bias and had relatively small sample
sizes, and most studies had short follow-
up periods. These deficiencies hamper
firm conclusions about the choice for
either the LNG-IUS or EA, which makes
counseling complicated.
Because of the advantages of the LNG-
IUS over EA in terms of invasiveness,
reversibility, contraceptive effect, and
feasibility in general practice, we per-
formed a multicenter RCT to investigate
if a strategy starting with the LNG-IUS is




This multicenter RCT was performed
between 2012 and 2016 in 26 hospitals
collaborating in the Dutch Consortium
for Studies in Women’s Health and
Reproduction and in a network of gen-
eral practices in the Netherlands. The
study was conducted according to the
principles of the Declaration of Helsinki
and approved by the ethics committee of
the Academic Medical Center in187.e2 American Journal of Obstetrics & GynecolAmsterdam, Netherlands (registration
number 2011_372). The study was
registered prospectively in the
Netherlands Trial Register (NL2842).
Full details of the protocol have been
published previously.20
After consultation with the Data and
Safety Monitoring Board (DSMB) on
September 19, 2012, an adjustment to
the protocol was made. The board
advised to change the primary outcome
from satisfaction to menstrual blood loss
(measured with the Pictorial Blood Loss
Assessment Chart [PBAC] score). The
reason for this change was that satisfac-
tion is a subjective outcome that depends
on women’s expectations about the
treatment and is therefore not an
objective outcome to measure the dif-
ference in treatment effect. The amount
of menstrual blood loss was considered
as a more objective outcome to measure
the difference in effectiveness. The
change in primary outcome was
approved by the ethics committee in
March 2013. At that time, 24 women had
been included in the study whose
collected data were not accessible by the
researchers.
Women were eligible if they had
HMB, with a PBAC score exceeding 150
points. Women could have received
previous treatment (oral) for HMB.
Women were excluded if they were
younger than 34 years; had a pregnancyogy FEBRUARY 2021wish; had an abnormal cervix cytology in
the past 5 years; had intracavitary fi-
broids, polyps, or large intramural fi-
broids; had a uterus length of>10 cm; or
had a uterine size>10 weeks of gestation
measured by either a transvaginal ultra-
sound or bimanual vaginal examination,
depending on the setting (general prac-
tice or gynecology department).
Eligible women were identified by the
gynecologists in the participating hos-
pitals or by the participating general
practitioners. Research nurses or treat-
ing physicians obtained written
informed consent from all participating
women before randomization.
Randomization and blinding
Consenting women were randomly
allocated in a 1:1 ratio to 1 of 2 treatment
arms by research nurses at the local
centers, using an internet-based
randomization module. Randomization
was performed in blocks, with a variable
block size of 2 or 4, and was stratified for
recruitment by the general practitioner
or gynecologist. Because of the nature of
the intervention, it was not possible to
blind the participants and their treating
physicians for the allocated treatment.
Interventions
The LNG-IUS (Mirena, Bayer Health-
Care Pharmaceuticals) is a T-shaped
device placed into the endometrial cav-
ity, containing a total of 52 mg of levo-
norgestrel, releasing 20 mg/d. The system
is licensed up to 5 years of use.21 Inser-
tion of the LNG-IUS is an outpatient
procedure, which can be performed
without anesthesia. In women allocated
to the LNG-IUS group, the device was
inserted by a gynecologist, resident, or
general practitioner skilled in inserting
the LNG-IUS.
The EA procedure was performed
with a bipolar radiofrequency device:
NovaSure system (NovaSure, Hologic,
Marlborough, MA), a nonresectoscopic
ablation technique that destroys the
uterine endometrium using radio-
frequency electrical energy.22,23 In
women allocated to EA group, the pro-
cedure was performed by a gynecologist
or resident experienced in treatment
with the NovaSure device. The
FIGURE 1
Trial profile
645 women meeting eligibility 
criteria
375 women excluded
• 295 declined to be randomised, 
follow-up in observational cohort 
• 80 declined to participate 
270 women randomly assigned
132 assigned to LNG-IUS 138 assigned to EA
130 received assigned intervention 
• 7 ablation not succeeded
8 did not receive assigned intervention 
• 5 had a preference for LNG-IUS 
• 2 decided to receive no intervention
• 1 unknown reason
0 ITT, 0 PP lost to follow-up 
6 ITT, 4 PP primary outcome missing*
27 women had a re-intervention
115 Analysed ITT (primary outcome)
112 Analysed PP (primary outcome)
5 ITT, 2 PP lost to follow-up 
12 ITT, 8 PP primary outcome missing*
44 women had a re-intervention
132 Analysed ITT (primary outcome)
119 Analysed PP (primary outcome)
122 received assigned intervention 
8 did not receive assigned intervention
• 4 had a preference for EA
• 3 decided to receive no intervention
• 1 unknown reason
2 unknown (lost to follow up from 
randomisation day)
*Women excluded for primary analysis but included for secondary analyses. See Table 3 for type of, number of, and reason for reinterventions.
EA, endometrial ablation; ITT, intention to treat; LNG-IUS, levonorgestrel-releasing intrauterine system; PP, per protocol.
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under local anesthetics or conscious
sedation or in the operating room under
general or spinal anesthesia depending
on the local setting.
Outcomes
The primary outcome was blood loss at
24 months after randomization,
measured with the PBAC score according
to Higham.24 To calculate this score,
women were asked to record their men-
strual blood loss for 1 month, counting
the number of super tampons or pads
used each day. The total score was
calculated using a score of 1 for each
lightly saturated tampon, 5 formoderately saturated tampons, and 10 for
completely saturated tampons. For pads,
the scoreswere 1, 5, and 20, respectively.24
Secondary outcome measures were
controlled bleeding, defined as a PBAC
score not exceeding 75 points,6 compli-
cations and reinterventions within 24
months after randomization, amenor-
rhea, spotting, dysmenorrhea, presence
of clots, duration of blood loss, satisfac-
tion with treatment (measured with a 5-
point Likert scale), QoL (measured with
the general 36-Item Short Form Health
Survey [SF-36] questionnaire and the
disease-specific Menorrhagia Multi-
Attribute Scale [MMAS, also known as
ShawMenorrhagia Questionnaire]),25e28FEBRUARY 2021 Ameriand sexual function (measured with the
Female Sexual Function Index [FSFI] and
Female Sexual Distress Scale [FSDS]).29,30
Women were required to complete
the questionnaires before treatment and
at 3, 6, 12, and 24 months after
randomization. Research nurses at the
local centers were responsible for col-
lecting baseline and follow-up data.
Serious adverse events (SAEs) were
monitored by the local investigator and
were reported within 7 days after noti-
fication. In addition, data on adverse
events were collected from medical re-
cords by the participating research
nurses and from the participant
questionnaires.can Journal of Obstetrics & Gynecology 187.e3
TABLE 1
Baseline characteristics
Characteristic LNG-IUS (n¼132) EA (n¼138)
Age, mean (SD) 44.7 (4.6) 45.3 (4.9)
BMI,a mean (SD) 27.5 (5.4) 27.8 (5.8)
Vaginal deliveries
0 25 (20.0) 23 (17.0)
1 15 (12.0) 26 (19.0)
>1 84 (68.0) 87 (64.0)
Cesarean delivery 30 (23.0) 23 (17.0)
Previous uterus surgery
Myomectomy 7 (5.3) 11 (8.0)
Polypectomy 4 (3.0) 5 (3.6)
Duration of HMB (mo),a median (IQR) 12.0 (6.0e28.0) 12.0 (5.0e24.0)
Previous treatmentb
Tranexamic acid 19 (14.0) 20 (14.0)
NSAIDs 7 (5.3) 10 (7.2)
Oral contraceptives 33 (25.0) 32 (23.0)
Progestogens 17 (13.0) 14 (10.0)
LNG-IUS 3 (2.3) 5 (3.6)
GnRH agonist 1 (0.8) 0 (0.0)
NuvaRing 0 (0.0) 1 (0.7)
Anticoagulants
Platelet aggregation inhibitors 2 (1.5) 1 (0.7)
Vitamin K antagonists 3 (2.3) 1 (0.7)
Current hormonal medication
Oral contraceptives 19 (14.0) 17 (12.0)
Progestogens 4 (3.0) 5 (3.6)
Dysmenorrheaa
Presence of dysmenorrhea 89 (73.0) 87 (67.0)
Mild 22 (18.0) 14 (11.0)
Moderate 38 (31.0) 36 (28.0)
Severe 29 (24.0) 37 (28.0)
Duration of menstruation (d), median (IQR) 8.0 (6.0e10.5) 7.0 (6.0e10.0)
PBAC score, mean (SD) 616.3 (524.3) 630.0 (551.8)
Values are given as number of women (percentage), unless otherwise indicated.
BMI, body mass index; EA, endometrial ablation; GnRH, gonadotropin-releasing hormone; HMB, heavy menstrual bleeding; IQR,
interquartile range; LNG-IUS, levonorgestrel-releasing intrauterine system; NSAID, nonsteroidal antiinflammatory drug;
NuvaRing, etonogestrel and ethinylestradiol vaginal ring; PBAC, Pictorial Blood Loss Assessment Chart; SD, standard deviation.
a Values were missing in some women; b Women could have received 1 previous treatment.
Beelen et al. Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding.
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We expressed the effectiveness of the
LNG-IUS relative to EA in terms of the
difference in mean PBAC score at 24187.e4 American Journal of Obstetrics & Gynecolmonths, using 95% confidence intervals
(CIs) to express statistical uncertainty.
Our primary analysis was an intention-
to-treat (ITT) analysis with theogy FEBRUARY 2021hypothesis that the LNG-IUS would be
noninferior to EA. Previous studies in
womenwith HMB have shown that a 50-
point difference in PBAC score between
treatments is clinically meaning-
ful.14,15,24,31 In an expert panel of 12
members, consisting of gynecologists,
general practitioners, and methodolo-
gists, a difference of maximally 25 points
was selected for expressing non-
inferiority. This margin was based on
results from previous studies and clin-
ical judgment, in which the practical
consequence of the difference in PBAC
score, translating it to the number of
tampons or pads being used, was taken
into account. Noninferiority of the
LNG-IUS treatment would be shown if
the upper limit of the 95% CI for the
difference in PBAC score did not
exceed the predetermined non-
inferiority margin of 25 points, with a
corresponding P value of <.05.
Accordingly, the statistical null hy-
pothesis for the trial was inferiority of
the LNG-IUS treatment compared with
EA treatment. With a P value of <.05,
this null hypothesis would be rejected,
and the alternative—noninferiority of
LNG-IUS treatment—accepted.
On the basis of previous studies, we
estimated the mean PBAC score at 24
months after randomization to be 50
points in the LNG-IUS group and 40
points in the EA group, with a stan-
dard deviation of 40 points.4,14e16,31,32
Allowing for a dropout rate of up to
15% and using an alpha of 5% and a
power of 80%, we aimed to recruit 266
women in total (133 women per arm).
After first analyzing the data, the dis-
tribution of the PBAC scores at 24
months follow-up was found to be
highly skewed with many zeros. This
rendered the assumptions of the initially
planned analysis, relying on the mean
difference and t test statistic, to be no
longer valid. Therefore, we calculated
the 95%CIs using bootstrapping (10.000
replications) and also relied on boot-
strapping to test the noninferiority hy-
pothesis. Because of the skewed
distribution, we additionally used a zero-
inflated negative-binomial model to
evaluate a difference in the primary
outcome measure.
TABLE 2
Menstruation pattern at 24 months of follow-up
Variable LNG-IUS (n¼115) EA (n¼132) Effect (RR) 95% CI P value
PBAC score, mean (SD) 64.8 (251.0) 14.2 (43.4) 50.50a 4.3e96.7b .87c
Amenorrhea 67 (58.0) 89 (67.0) 0.86 0.71e1.05
75 100 (87.0) 124 (94.0) 0.93 0.85e1.01
>75e150 9 (7.8) 6 (4.5) 1.72 0.63e4.69
>150 6 (5.2) 2 (1.5) 3.44 0.71e16.7
Duration of blood loss 7 d 105 (91.0) 126 (95.0) 0.96 0.89e1.02
Spotting 21 (18.0) 18 (14) 1.34 0.75e2.39
Presence of clots 7 (6.1) 4 (3.0) 2.01 0.60e6.69
Presence of dysmenorrhea 27 (23.0) 19 (14.0) 1.63 0.96e2.77
Mild 11 (9.6) 6 (4.5) — —
Moderate 10 (8.7) 7 (5.3) — —
Severe 6 (5.2) 6 (4.5) — —
Intention-to-treat analysis. Values are given as number of women (percentage), unless otherwise indicated.
CI, confidence interval; EA, endometrial ablation; LNG-IUS, levonorgestrel-releasing intrauterine system; PBAC, Pictorial Blood Loss Assessment Chart; RR, relative risk; SD, standard deviation.
a Mean difference; b CI calculated using bootstrapping (2.5th percentile and 97.5th percentile); c P value for noninferiority.
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inferiority trial in the ITT study group
may bias the results toward equivalence,
we performed an additional per-
protocol analysis of the primary
outcome measure, including all women
who received the allocated treatment.
Relative risks (RRs) or mean differ-
ences were estimated for secondary
outcomes at different time points, with
95% CIs. Secondary outcomes were
analyzed according to the ITT principle.
We plotted Kaplan-Meier curves for the
time between randomization and first
surgical reintervention and evaluated
differences using log-rank statistics. Data
on QoL and sexual function scores were
analyzed using a generalized linear
model for repeated measures (general-
ized estimating equation).
For the primary outcome, no impu-
tationwas used for missing data. Missing
data on secondary outcomes were not
imputed if a complete questionnaire at a
follow-up point was missing.
All statistical tests were performed with
a significance level of .05. Statistical ana-
lyses were performed using the software
Statistical Package for the Social Sciences
(SPSS version 25; SPSS Inc, Chicago, IL).
Longitudinal data analyses and analysesusing the zero-inflated negative binomial
model were performed using SAS
(version 9.4; SAS Institute, Cary, NC).
Bootstrapping was performed using the
Stata software (release 15; StataCorp LLC,
College Station, TX). In agreement with
the DSMB, no interim analysis was per-
formed. The statistical analyses are




Between April 27, 2012, and January 12,
2016, 645 women were registered as
eligible, of whom 270 provided
informed consent. Of the women who
declined to be randomized, 295 women
agreed to be followed up in an observa-
tional cohort study. Baseline character-
istics of women randomized and women
in the observational cohort were largely
comparable (Supplemental Table 1).
The 270 women were randomly
assigned to initial treatment with the
LNG-IUS (N¼132) or treatment with EA
(N¼138) (Figure 1). Baseline character-
istics of the 2 treatment groups were
comparable (Table 1).
Of the 132 women allocated to the
LNG-IUS group, 122 (92%) had anFEBRUARY 2021 AmeriLNG-IUS inserted, within amedian time
of 7 days from randomization (inter-
quartile range [IQR], 0e21) (Figure 1).
Of the 138 women allocated to the EA
group, 130 (94%) underwent the
assigned intervention, within a median
time of 27 days from randomization
(IQR, 13e48) (Figure 1). In 7 of 130
women (5.4%) who underwent EA, the
ablation could not be completed
(Supplemental Table 2).
Primary outcome
The PBAC score was obtained for 247 of
270 women (91%) at 24 months’ follow-
up (Figure 1). Themean PBAC score was
64.8 in the LNG-IUS group vs 14.2 in the
EA group (mean difference, 50.5; 95%
CI, 4.3e96.7) (Table 2; Supplemental
Figure 1). As the upper limit of the
95% CI exceeds the noninferiority
margin of 25 points, noninferiority of
the LNG-IUS could not be demonstrated
(noninferiority, P¼.87). The P value for
the per-protocol analysis was identical
(Supplemental Table 3).
Analysis of the primary outcome us-
ing a zero-inflated negative binomial
model showed a significant difference in
the PBAC score at 24 months for the
negative binomial component, owing tocan Journal of Obstetrics & Gynecology 187.e5
FIGURE 2
PBAC scores at baseline and 3, 6, 12, and 24 months
Mean PBAC-score









































Intention-to-treat analysis. Mean PBAC scores (SD), total number of women shown at each time
point. I bars indicate 95% confidence intervals.
EA, endometrial ablation; LNG-IUS, levonorgestrel-releasing intrauterine system; SD, standard deviation.
Beelen et al. Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding. Am J
Obstet Gynecol 2021.
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(4.09; 95% CI, 1.81e9.25) and a
nonsignificant odds ratio for the pro-
portion of womenwith zero scores (0.78;
95% CI, 0.35e1.72).
A robust decline in PBAC scores in
both groups was observed between base-
line and 3 months’ follow-up (Figure 2).
At 3 months after randomization, 60% of
women in the LNG-IUS group had
reached a PBAC score not exceeding 75
points compared with 83% of women in
the EA group (RR, 0.72; 95% CI,
0.59e0.87) (Supplemental Figure 2).
There was substantial variability in PBAC
scores in the LNG-IUS group at 24
months; 4women (3.5%) still had aPBAC
score of >750 points (Supplemental
Figure 2). In 100 of 115 women (87%)
in the LNG-IUS group and 124 of 132
women (94%) in the EA group, the PBAC
score had decreased to <75 points (RR,
0.93; 95% CI, 0.85e1.01) (Table 2;
Supplemental Figure 2).
Secondary outcomes
No significant differences were found for
secondary outcomes on menstruation
pattern (amenorrhea, duration of blood187.e6 American Journal of Obstetrics & Gynecolloss, spotting, presence of clots, and
dysmenorrhea) (Table 2).
The LNG-IUS was removed in 49
women (39%) in the LNG-IUS group.
Women who started with the LNG-IUS
were more likely to receive a surgical or
drug reintervention within 24 months
compared with women in the EA group
(44/127 [35%] vs 27/138 [20%]; RR, 1.77;
95% CI, 1.17e2.68) (Table 3;
Supplemental Figures 3 and 4). In the
LNG-IUS group, 34 women (27%) ulti-
mately received a surgical intervention,
31 women (24%) underwent EA, and 9
women (7.1%) underwent a hysterec-
tomy (of which 6 women had previously
undergone EA). In the EA group, 14
women (10%) underwent a hysterec-
tomy. Most surgical reinterventions were
performed within the first year after
treatment (26/34 [76%] in the LNG-IUS
group and 10/14 [71%] in the EA
group) (Supplemental Figure 5). Addi-
tional drug treatment was prescribed to
19 women (15%) in the LNG-IUS group
vs 13 (9.4%) in the EA group (RR, 1.59;
95% CI, 0.82e3.08). The most common
reason for a reintervention in both groups
was persistence of HMB (Table 3).ogy FEBRUARY 2021Up to 12 months of follow-up, satis-
faction rates were significantly higher in
women in the EA group compared with
women in the LNG-IUS group
(Supplemental Table 4; Figure 3). At 24
months of follow-up, 74 of 100 women
(74%) in the LNG-IUS group were
satisfied with their treatment compared
with 98 of 116 women (84%) in the EA
group (RR, 0.88; 95% CI, 0.76e1.01).
SF-36 scores were significantly lower
over time in the LNG-IUS group for 4 of
9 domains (physical functioning, phys-
ical role, social functioning, and health
change), compared with the EA group
(between 2.3 and 7.6 points difference;
scale of 0e100) (Supplemental Table 5).
No significant differences were found in
MMAS summary scores (mean differ-
ence, 3.3; 95% CI, 0.5 to 7.1)
(Supplemental Table 6; Supplemental
Figure 6) and in sexual function (FSFI)
and distress (FSDS) scores over time
(Supplemental Tables 7 and 8).
There were 13 SAEs in the LNG-IUS
group and 8 SAEs in the EA group
(Supplemental Table 9). Moreover, 1
SAE in the LNG-IUS group was possibly
related to the intervention (tuboovarian
abscess) vs 4 SAEs in the EA group
(hematometra, endometritis, anaphy-
lactic reaction on premedication, and
observation for acute abdominal pain).
Discussion
Principal findings of the study
Both the strategy starting with an LNG-
IUS and the strategy starting with EA
lead to a large decrease in menstrual
blood loss, with comparable QoL and
satisfaction scores. In most women in
both the LNG-IUS and EA groups, the
PBAC score decreased to a level not
exceeding 75 points, indicating
controlled bleeding. Nevertheless, there
was a significant difference in the mean
score, in favor of EA, and we could not
demonstrate noninferiority of the LNG-
IUS strategy.
The LNG-IUS was removed in 39% of
the women in the LNG-IUS group
within the 24 months of follow-up. The
risk of receiving an additional interven-
tion was almost twice as high in women
who started with the LNG-IUS
compared with women who started
TABLE 3
Type and number of reinterventions after 24 months of follow-up
Variable LNG-IUS (n¼127) EA (n¼138) Effect (RR) 95% CI
No. of women who discontinued the primary interventiona,b 55 (43.0) 27 (20.0) 2.21 1.49e3.28
No. of women with reinterventionsb 44 (35.0) 27 (20.0) 1.77 1.17e2.68
No. of women with LNG-IUS removal 49 (39.0) N/A — —
No. of women with surgical reinterventionsb 34 (27.0) 14 (10.0) 2.64 1.49e4.68
Endometrial ablation 31 (24.0) 1 (0.7) — —
First generation 1 (0.8) 1 (0.7) — —
Second generation 30 (24.0) 0 (0.0) — —
Hysterectomy 9 (7.1) 14 (10.0) 0.70 0.31e1.56
No. of women with drug reinterventionsb 19 (15.0) 13 (9.4) 1.59 0.82e3.08
Reason for reinterventionc,d
HMB persisting 42 (63.0) 18 (53.0) — —
Dysmenorrhea 10 (15.0) 3 (8.8) — —
Pelvic pain 8 (12.0) 3 (8.8) — —
Spotting 7 (10.0) 1 (2.9) — —
Side effect 15 (22.0) 1 (2.9) — —
Lost LNG-IUS 8 (12.0) N/A — —
Hematometra 1 (1.5) 1 (2.9) — —
Othere 2 (3.0) 2 (5.9) — —
Values are given as number of women (percentage), unless otherwise indicated.
CI, confidence interval; EA, endometrial ablation; HMB, heavy menstrual bleeding; LNG-IUS, levonorgestrel-releasing intrauterine system; N/A, not applicable; RR, relative risk.
a Women who received a reintervention and/or removed the LNG-IUS; b Women who received1 reintervention; c Women who indicated1 reason for a reintervention; d Percentages are calculated
over total number of reinterventions: LNG-IUS group (n¼67) and EA group (n¼34); e Comorbidity (n¼3) and malposition LNG-IUS (n¼1). For a complete overview of reinterventions, see
Supplemental Figures 3 and 4 (Appendix).
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tion was not performed in almost three-
quarters of the women in the LNG-IUS
group, and hysterectomy rates did not
differ significantly between the 2 treat-
ment groups.
We found no differences over time
between the 2 strategies in disease-
specific QoL and sexual functioning.
General QoL scores were significantly
better for 4 of 9 domains in the EA
group; however, this difference was small
(2.3e7.6 points on a 100-point scale),
making it debatable whether this differ-
ence is clinically relevant.
Results
In the first 6 months after treatment, a
significantly larger percentage of women
in the EA group were satisfied and had
reached a level of controlled bleeding.
This difference can be explained by thedifferentmechanisms of action. Although
EAworks immediately after treatment, in
the first months after insertion of the
LNG-IUS, irregular bleeding and spotting
are frequent side effects.21
The percentage of women in the LNG-
IUS group who underwent a surgical
reintervention (27%) was higher in our
trial than in a trial in which the LNG-IUS
was compared with oral medication
(clinical effectiveness and cost-
effectiveness of levonorgestrel-releasing
intrauterine system in primary care
against standard treatment for menor-
rhagia [ECLIPSE] trial) (4% EA and 6%
hysterectomy at 2 years), although the
reported discontinuation rate was similar
(36% in the ECLIPSE trial and 39% in
our trial).3 The 5-year follow-up of the
ECLIPSE trial showed a doubling of sur-
gical reintervention rates (20% of
women).33 The observed difference inFEBRUARY 2021 Amerisurgical reintervention rates can be
explained by the difference in compara-
tive treatment. As in our trial, the LNG-
IUS was compared with EA; all partici-
pating women agreed to have 1 of these
treatments, making them less inclined to
preserve conservative treatment.
Furthermore, the ECLIPSE trial was per-
formed in a primary care setting, where
EA is not the standard of care. Although
in earlier research it was found that
women prefer a treatment with no need
for a repeat procedure,34 we did find
comparable satisfaction rates at 24
months of follow-up.
Research implications
To investigate differences in costs be-
tween the 2 treatment strategies, we have
planned to perform a cost-effectiveness
analysis. Future research could further
focus on prognostic factors that cancan Journal of Obstetrics & Gynecology 187.e7
FIGURE 3
Satisfaction rates at 3, 6, 12, and 24 months
No. of women satisfied
LNG-IUS 40/ 92 (43%) 57/ 96 (59%) 62/ 83 (75%) 74/ 100 (74%)
EA 82/ 101 (81%) 95/ 110 (86%) 91/ 104 (88%) 98/ 116 (84%)
Effect (RR) 0.54 (95% CI 0.42 - 0.69) 0.69 (95% CI 0.57 - 0.82) 0.85 (95% CI 0.74 - 0.99) 0.88 (95% CI 0.76 - 1.01)
LNG-IUS EA
3 months 6 months 12 months 24 months















Intention-to-treat analysis. Number of women/total number of women (%) and RR (95% CI) shown at
each time point.
CI, confidence interval; EA, endometrial ablation; LNG-IUS, levonorgestrel-releasing intrauterine system; RR, relative risk.
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LNG-IUS or EA and the construction of
an individualized prediction model,
allowing more personalized counseling
of women with HMB while decreasing
the chances of treatment failure.
Strengths and limitations
Key strengths of our trial are its multi-
center design,withwomen recruited from
both primary care and secondary care; a
sample size larger than that of previous
trials; the long follow-up period; and the
relatively low number of women who
were lost to follow-up for the primary
outcome. The strategies evaluated in this
pragmatic RCTreflect current practice, in
which women can change or discontinue
the initial treatment. Another strength is
the limited set of exclusion criteria,
making the results of this study general-
izable to many women with HMB.
Although a substantial number of women
declined to be randomized, baseline
characteristics of these women were
largely comparable to the randomized
women.187.e8 American Journal of Obstetrics & GynecolBecause women were allowed to
receive a reintervention during the
follow-up period, all outcomes reflect
the effect of a strategy, not just of the
allocated intervention. Blinding of the
participants was not possible, so de-
cisions about reinterventions could be
influenced by the initial preference and
expectations of the participants and
physicians.
Currently, there is no consensus about
the preferable outcomemeasure in HMB
studies, and a wide variety of treatment
outcomes are being used.35 The most
frequently used measures are blood
losserelated outcome measures.35,36
Our primary outcome measure was the
PBAC score, which was found to be
significantly associated with satisfaction
and the chance of receiving a reinter-
vention.37 As HMB has a major impact
on women’s well-being, we thought it
important to pay special attention to
QoL and sexual functioning as well. By
combining the PBAC score with these
secondary outcomes, we aimed to
generate a broad assessment of theogy FEBRUARY 2021effectiveness of both treatments.38 At the
moment, the CoreOutcomeMeasures in
Effectiveness Trials initiative is working
on a core outcome set for HMB that
covers all aspects of the condition, which




This study showed that a strategy start-
ing with the LNG-IUS and a strategy
starting with EA lead to controlled
bleeding in most women with compa-
rable satisfaction, QoL, and sexual
function scores. With both strategies, a
large decrease in menstrual blood loss
was found. Nevertheless, the mean score
at 24 months was lower in the EA group,
and we could not demonstrate non-
inferiority of the LNG-IUS strategy.
Women who started with the LNG-IUS
more frequently had further treatment,
with a quarter of the women undergoing
EA.
The results of this study will enable
physicians to provide women with clear
information about multiple important
outcomes after HMB treatment. For
instance, the faster reduction in men-
strual blood loss and lower chance of
needing additional treatment of EA can
be weighed against the less-invasive and
reversible characteristics of the LNG-
IUS. On the basis of the treatment out-
comes reported here, women with HMB
should be able to make a well-informed
decision about treatment. n
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